Charleston Hematology Oncology Associates

Charleston, South Carolina 29414

1 studies enrolling now · 22 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Cancer, Breast Cancer, CRPC, Cachexia, Carcinoma, Pancreatic Ductal, Castration-resistant Prostate Cancer, Chronic Myelomonocytic Leukemia, Diffuse Large B-cell Lymphoma, Ductal Adrenocarcinoma, Early Stage HER2+ Breast Cancer, Exocrine Pancreatic Cancer

Studies at this site

• A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) — Enrolling by invitation
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Running, not enrolling
• Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) — Stopped early
• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML — Completed
• A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma — Completed
• Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL — Completed
• CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma — Stopped early
• Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) — Completed
• An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide — Completed
• Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer — Completed
• Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer — Stopped early
• TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) — Stopped early
• A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma — Completed
• Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer — Stopped early
• Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma — Completed
• A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer — Withdrawn before enrolling
• A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer — Completed
• To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS. — Stopped early
• Study of GTx-024 on Muscle Wasting (Cachexia) Cancer. — Completed
• 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy — Completed
• Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine — Completed
• APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer — Completed